MedPath

Clinical and Radiographic Evaluation of Mineral Trioxide Aggregate and Human Amniotic Membrane in Primary Molar Teeth

A study comparing the outcomes of pulpotomy using Mineral Trioxide Aggregate (MTA) and Human Amniotic Membrane (HAM) in primary molar teeth found both materials to have 100% clinical success. However, HAM showed a significant reduction in periodontal ligament widening over time, suggesting it as a favorable alternative to MTA for pulpotomy in primary teeth.

The study aimed to clinically and radiographically compare the outcomes of pulpotomy using Mineral Trioxide Aggregate (MTA) and Human Amniotic Membrane (HAM) in primary molar teeth at 1, 3, 6, and 12 months. It was a randomized clinical trial with two groups: one treated with MTA (group I) and the other with HAM (group II).
Results indicated that both MTA and HAM exhibited 100% clinical success, with no signs of external resorption, periapical bone destruction, or internal resorption observed in either group at all four time intervals. However, periodontal ligament widening was noted in 30% of the MTA group participants at 1-month and 12-month follow-ups. In contrast, the HAM group showed a significant reduction in periodontal ligament widening, decreasing from 22.2% at 1-month to 11.1% at the 12-month follow-up.
The study concluded that HAM demonstrated favorable clinical and radiographic outcomes, advocating for its use as an alternative to MTA for pulpotomy in primary teeth. HAM is highlighted for its ease of availability, cost-effectiveness, ease of handling, and its ability to favor tissue regeneration, addressing the need for newer, effective agents beyond MTA.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Mineral Trioxide Aggregate in Indirect Pulp Capping

A randomized clinical trial compared the effectiveness of Silver Diamine Fluoride (SDF) and Mineral Trioxide Aggregate (MTA) in indirect pulp capping (IPC) for first permanent molars with deep carious lesions. Both materials showed a 100% clinical and radiographic success rate after 12 months, with no significant differences in dentin bridge thickness. The study highlights the potential of SDF as a cost-effective alternative to MTA for IPC in permanent teeth, despite the need for further research.

Orca-T Demonstrates Promising Outcomes in Hematologic Malignancies

Orca-T, an allogeneic T-cell immunotherapy, shows safety and feasibility in reduced-intensity stem cell transplant for advanced hematologic malignancies.
A retrospective analysis indicates improved overall survival with Orca-T compared to post-transplant cyclophosphamide in high-risk patients.

Outcomes Remain Poor for Myeloproliferative Neoplasm Blast Phase Despite New Therapies

A recent study in _Blood Advances_ highlights that the median overall survival for patients with myeloproliferative neoplasm blast phase (MPN-AP/BP) remains poor at 0.86 years, despite modern therapies.
The research found no significant difference in survival based on first-line treatment strategies, including intensive chemotherapy and venetoclax-based regimens, indicating a lack of optimal pre-transplant strategy.

TransCon PTH Demonstrates Sustained Skeletal Benefits in Hypoparathyroidism Patients: 3-Year Data

Ascendis Pharma's TransCon PTH (palopegteriparatide) normalized bone remodeling in adults with hypoparathyroidism after 162 weeks of treatment.
The Phase 2 PaTH Forward Trial results suggest long-term palopegteriparatide treatment promotes skeletal health, mirroring that of parathyroid sufficiency.

Tapotoclax Shows Limited Efficacy in Myelodysplastic Syndromes After HMA Failure

Tapotoclax demonstrated a manageable safety profile in high-risk MDS patients who had previously failed hypomethylating agents (HMAs), according to a phase 1 study.
Although no objective responses were observed, some patients experienced reductions in bone marrow blasts and decreased transfusion dependence.

TriClip TEER Shows Sustained Benefits in Tricuspid Regurgitation at 3 Years

Transcatheter edge-to-edge repair (TEER) using Abbott's TriClip device significantly reduces tricuspid regurgitation (TR) to moderate or less in 79% of patients.
The reduction in TR observed after one year with TriClip was sustained at three years, indicating long-term efficacy of the treatment.

Light-Activated Therapy Shows Promise in Improving Oral Health for Adolescents with Braces

A clinical trial is underway to assess light-activated antibacterial therapy's effectiveness in improving plaque control for adolescents with braces.
The Lumoral device, combining antibacterial blue and red light with a photosensitive mouth rinse, aims to reduce harmful bacteria and plaque buildup.

CAMZYOS Demonstrates Sustained Benefits in Obstructive Hypertrophic Cardiomyopathy Trial

Long-term follow-up data from the EXPLORER-LTE trial shows CAMZYOS (mavacamten) maintains efficacy and safety in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Patients treated with CAMZYOS experienced consistent improvements in echocardiographic measures and biomarkers, such as resting LVOT gradient and NT-proBNP levels, over 3.5 years.

MATTERHORN Trial: TEER Non-Inferior to Surgery for Secondary Mitral Regurgitation

The MATTERHORN trial demonstrated that transcatheter edge-to-edge repair (TEER) is non-inferior to surgery in treating secondary mitral regurgitation (MR) at one year.
Both TEER and surgery effectively improved MR, with a similar rate of MR grade ≤1 observed in both groups after one year, indicating comparable efficacy.

Clinical and Radiographic Evaluation of Biodentine in Revascularization of Non-Vital Immature Teeth

A study comparing the clinical and radiographic outcomes of using Biodentine versus white Mineral Trioxide Aggregate as coronal plug materials in the revascularization of non-vital immature teeth found no significant difference in success rates or root length increase, but a notable difference in tooth discoloration.

Reference News

[1]
Clinical and Radiographic Evaluation of Mineral Trioxide ...
pubmed.ncbi.nlm.nih.gov · Jun 10, 2024

Study compared MTA and HAM for pulpotomy in primary molars over 1, 3, 6, and 12 months. Both showed 100% clinical succes...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy